Table 1.
Baseline patient characteristics, treatment selections and clinical outcomes
| Characteristic/Clinical response | Patients (total n=34) |
| Age, median (range) | 61 (41–79) |
| Male sex, n (%) | 20 (59) |
| ECOG PS score, n (%) | |
| 0 | 8 (24) |
| 1 | 17 (50) |
| 2 | 7 (21) |
| 3 | 1 |
| Unknown | 1 |
| IMDC risk score, n (%) | |
| 0 | 4 (12) |
| 1 | 12 (35) |
| 2 | 14 (41) |
| 3 | 3 (9) |
| 4 | 1 (3) |
| Tissue specimen, n (%) | |
| Primary | 24 (71) |
| Metastatic | 10 (29) |
| Line of therapy, n (%) | |
| First line | 4 (12) |
| Second line | 15 (44) |
| Third line or after | 15 (44) |
| Checkpoint inhibitor treatment, n (%) | |
| Nivolumab | 31 (91) |
| Ipilimumab/Nivolumab | 2 (6) |
| Pembrolizumab | 1 (3) |
| Number of doses, median (range) | 9.5 (1–56) |
| Time on ICI, median (range) | 4.8 months (0–24) |
| Follow-up, median (range) | 9.1 months (1–31) |
| Best response (n; %) | |
| Disease control (n=16; 47%) | |
| Complete response | 2 (6) |
| Partial response | 5 (15) |
| Stable disease | 9 (26) |
| Progressive disease (n=18; 53%) | |
| Progressive disease | 18 (53) |
| Treatment discontinuation reason | |
| Disease progression | 24 |
| Immune-mediated toxicity | 2 |
ECOG, Eastern Cooperative Oncology Group.